.png)
CTI Life Sciences Fund Launches Oligon Therapeutics
CTI Life Sciences Fund (CTI) has launched Oligon Therapeutics (OligonTx), a new biotechnology company pioneering RNA-based multi-targeting drugs as novel treatments
SeekR drug is administered systemically as an injectable, without special formulation
Integrates two folded RNA oligo-binders (aptamers) flanking two siRNA silencers
Dual binders for precision in delivery, dual siRNA for controlled reprograming
Unprecedented efficiency and selectivity to get into any cellular subtype, including T-cells, and cancer cells
Oligon's proprietary SeekR platform technology integrates dual oligo-binders (RNA aptamers that function like chemical antibodies designed to selectively bind target proteins) with dual oligo-silencers (siRNA) into a single self delivering SeekR drug. The dual oligo-binders are engineered to seek out and cross link two specific cell surface receptors, which achieves unprecedented selectivity for delivery to the right cell subtypes, and triggers highly efficient cellular internalization through receptor cross linking mediated endocytosis. Once internalized into the right cell type, the dual siRNA induce multi-targeted RNAi for precise control of cellular programs to achieve the desired therapeutic effect.
SeekRs have two oligo-binders flanking a double stranded bridge in the middle that encodes two siRNA. This very unique structure is just the right size and flexible shape to effectively bridge and cross-link two cell surface receptors. This bivalent interaction leads to a high avidity interaction that can trigger about a ten fold improvement in the efficiency of cellular internalization through receptor mediated endocytosis. The internalized SeekR releases the siRNA encoded on the double stranded bridge, which in turn persist to drive the intended RNAi phenotype.
Innovations in AI based molecular modeling have transformed how our scientists discover and optimize RNA oligo-binder interactions with target cell surface receptor proteins
Learn about SeekR Programs currently in development at Oligon
Chief Executive Officer
Chief Operating Officer
Chief Scientific Officer
Chief Information Officer
RNA Research
Laboratories
World-Leading
AI Researchers
University Students in Life Sciences Programs
Annual R&D
Funding
Square Feet of
Lab & GMP Space
Life Sciences
Companies
September 14, 2025
CTI Life Sciences Fund (CTI) has launched Oligon Therapeutics (OligonTx), a new biotechnology company pioneering RNA-based multi-targeting drugs as novel treatments
We are excited to answer your questions, and to explore opportunities to collaborate.
